5-甲基-2,1,3-苯并噁二唑 | 20304-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 5-甲基-2,1,3-苯并噁二唑
• 中文别名: 5-甲基-2,1,3-苯并恶二唑；5-甲基苯并呋咱
• 英文名称: 5-methyl-benzo[1,2,5]oxadiazole
• 英文别名: 5-Methylbenzofurazan；5-methylbenzo[c][1,2,5]oxadiazole；5-methyl-2,1,3-benzoxadiazole
• CAS: 20304-86-3
• 化学式: C₇H₆N₂O
• mdl: MFCD00068073
• 分子量: 134.137
• InChiKey: RRZFDFYIDRCBCQ-UHFFFAOYSA-N

物化性质

• 熔点：
  33-35°C
• 沸点：
  209.2±33.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-甲基-2,1,3-苯并噁二唑 在 氢溴酸 、 溴 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 5-甲基-2,1,3-苯并恶二唑-4-甲腈
  参考文献：
  名称：

  Pilgram,K.; Zupan,M., Journal of Heterocyclic Chemistry, 1974, vol. 11, p. 813 - 814

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基-2-硝基-N-乙酰基苯胺 在 ammonium chloride 、 锌 作用下， 生成 5-甲基-2,1,3-苯并噁二唑
  参考文献：
  名称：

  Green; Rowe, Journal of the Chemical Society, 1917, vol. 111, p. 618

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• Formation of phospholimine and novel preparation of benzofurazans by thermolytic rearrangement of N-(o-nitroaryl)-1,2,5-triphenylphospholimines
  作者：J. I. G. Cadogan、R. Gee、R. J. Scott

  DOI：10.1039/c3972001242a

  日期：——

  5-triphenylphosphole with aryl-, arylsulphonyl-, methylsulphonyl-, ethoxycarbonyl-, and diphenylphosphinyl-azides readily give the novel 1,2,5-triphenylphospholimines (I; X = Ar, ArSO2, MeSO2, EtO2C, Ph2PO) which are thermally stable except for N-o-nitroaryl derivatives, e.g.(III), which give benzofurazans and 1,2,5-triphenylphosphole oxide, a reaction which does not occur with the corresponding P-triphenyl-or P-trithoxy-derivatives

  1,2,5-三苯基膦与芳基-，芳基磺酰基-，甲基磺酰基-，乙氧基羰基-和二苯基次膦酰基叠氮化物的反应轻松获得了新的1,2,5-三苯基膦酰亚胺（I; X = Ar，ArSO 2，MeSO 2，环氧乙烷2 C，博士2 PO）具有热除了稳定ñ - ö -nitroaryl衍生物，例如（III），这给benzofurazans和1,2,5- triphenylphosphole氧化物，其不与所述相应发生反应P -三苯基-或P -trithoxy衍生物[PH 3 P = NAR或（ETO）3 P = NAR]。
• The reactivity of organophosphorus compounds. Part XXX. Iminophospholes and a new synthesis of benzofurazans via intramolecular rearrangement of 1-o-nitroarylimino-1,2,5-triphenylphospholes
  作者：J. I. G. Cadogan、Robert J. Scott、Robert D. Gee、Ian Gosney

  DOI：10.1039/p19740001694

  日期：——

  1-aroylimino-1,2,5-triphenylphospholes (2; X = PhCO and p-NO2·C6H4CO), but these decomposed at this temperature to give the corresponding aryl cyanides and the phosphole oxide. The use of copper-bronze reduced the decomposition point of the dioxazolidin-2-ones sufficiently for the iminophospholes to be isolated. Base catalysed decomposition of ethyl N-(p-nitrophenylsulphonyloxy)carbamate (4) in the presence of

  已经合成了一系列的N-取代的1-亚氨基-1,2,5-三苯基磷（2）。芳基，甲磺酰基，芳基磺酰基，乙氧基羰基，苯氧基羰基和二苯基次膦酰基叠氮化物与1,2,5-三苯基膦的反应得到相应的N-取代的1-亚氨基膦[2; X = Ar，MeSO 2，ArSO 2，EtO 2 C，PhO 2 C和Ph 2 P（O）]，通过非亚硝基苯路线的收率很高。甲苯磺酰磷（2； X =甲苯磺酰基）也是通过无水氯胺-T反应制得的。与磷脂。苯甲酰叠氮化物通过分解反应，然后进行库尔修斯重排反应，而不是与相对较弱的亲核性1,2,5-三苯基磷脂反应（参见Ph 3 P）。缺电子的4-硝基苯甲酰基和2,4-二硝基苯甲酰基叠氮化物给出相应的1-芳基氨基-1,2,5-三苯基磷[2; X = C 6 H ^ 4 NO 2 - p和2,4-（NO 2）2 C ^ 6 ħ 3在6和55％的产率分别]。在铜存在下的5，7-二甲基四唑并[1，5-
• Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same
  申请人：BOURRIE Bernard

  公开号：US20080176874A1

  公开（公告）日：2008-07-24

  The invention relates to derivatives of pyrido[2,3-d]pyrimidine, to the preparation thereof, and to the therapeutic application of the same.

  本发明涉及吡啶并[2,3-d]嘧啶衍生物，其制备方法以及它们的药用应用。
• Non-steroid progesterone receptor agonist and antagonist and compounds
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05808139A1

  公开（公告）日：1998-09-15

  Non-steroidal compounds which are high affinity, high specificity ligands for progesterone receptors are disclosed. The compounds include synthetic derivatives of cyclocymopol and its diastereomers, spectroscopically and chromatographically pure (3R)-cyclocymopol monomethyl ether, which functions as a progesterone receptor antagonist, and spectroscopically and chromatographically pure (3S)-cyclocymopol monomethyl ether, which functions as a progesterone receptor agonist. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by progesterone receptors and for treating patients requiring progesterone receptor agonist or antagonist therapy.

  公开了与孕酮受体具有高亲和力、高特异性的非甾体化合物。这些化合物包括环状赛波尔的合成衍生物及其对映异构体，光谱和色谱纯(3R)-环状赛波尔甲醚，其作为孕酮受体拮抗剂，以及光谱和色谱纯(3S)-环状赛波尔甲醚，其作为孕酮受体激动剂。还公开了利用所述化合物调节孕酮受体介导的过程以及治疗需要孕酮受体激动剂或拮抗剂治疗的患者的方法。

表征谱图